CYRUS A. CHOWDHURY

Managing Director and Chief Executive Officer

Mr. Chowdhury's career has focused on global market access issues across six continents, split evenly between emerging markets (BRIC-MT and through the top 73 emerging markets) and developed markets (EU-5, Japan, Australia and Canada). His achievements include successful assignments in pharmaceutical and medical technology price integrity, payer partnerships, innovative access schemes, patient access programmes, customer value approach, and portfolio-level global market access strategies. While with Genzyme, he developed the company's first parallel trade pricing defense strategy. While with Cambridge Pharma Consultancy (now part of IMS), Mr. Chowdhury played an integral role in launching the firm's Greater China market access consulting practice, spending much of his time focusing on pan-Asian issues. Additionally, Mr. Chowdhury served as a research specialist with the London School of Economics, WHO and European Observatory on Health for Central and Eastern Europe. Prior to founding CBPartners, Mr. Chowdhury founded and led the Global Market Access practice at ISA.

Mr. Chowdhury holds an Masters in International Health Policy from the London School of Economics, and a Bachelors in Neuroscience from Boston University.

MONICA MARTIN DE BUSTAMANTE

Managing Director

Ms. Martin de Bustamante's career has focused on pharmaceutical global pricing and market access issues for biopharmaceutical and pharmaceutical products. Her time has been apportioned between the emerging and mature markets, with a strong focus on Latin America (Mexico, Argentina, Colombia, Brazil), Asia (China, India, Philippines, Thailand) and Southern Europe (Spain, Italy). Through thousands of in-depth interviews conducted in the countries' native languages Ms. Martin de Bustamante has fortified her understanding of how these markets are rapidly evolving cost-containment policy.

Much of Ms. Martin de Bustamante's work to date has centred around understanding the barriers to access and reimbursement challenges posed by developing economies in the emerging markets and the continuous reforms throughout Europe. She has extensive international experience in price integrity, global market access strategies, therapeutic area financing trends, payer-based biosimilar strategy, and patient assistance programs.

Ms. Martin de Bustamante holds a Bachelors in Biomedical Engineering and a Bachelors in Romance Languages & Engineering Sciences from Dartmouth College. She is fluent in Spanish and Italian.

RACHEL BECKERMAN, PHD

Principal

Dr. Beckerman has almost a decade of experience in the biopharmaceutical industry, including her focus on value assessment for innovative assets. Her expertise spans several therapeutic areas, with emphasis on oncology and autoimmune disorders.

During her time with the firm, Dr. Beckerman has supported clients on the development of value platforms, clinical data evidence packaging, value messaging. Her work is centred around value demonstration to HTA agencies and access authorities in mature and emerging markets. She has specifically developed a core expertise in building global and market-level value dossiers, including health economic models.

Dr. Beckerman's past few years have seen her developing innovative approaches to pricing and reimbursement optimised clinical trial design, particularly addressing the variant needs of different access authorities around the world.

Dr. Beckerman holds a Doctor of Philosophy in Biochemistry and Molecular Biophysics from Columbia University, as well as a Bachelors in Biochemistry from McGill University. She is fluent in French.

KEVIN WONG, PHD

Principal

Dr. Wong's extensive career balances both global strategic consulting and commercial brand planning within industry.

His most recent experience includes leading Genentech / Roche's initiative to define franchise strategy in distinct and overlapping therapeutic markets. Additionally, he led competitive intelligence teams to define and limit brand planning blind-spots. Dr. Wong also served on the global launch readiness team responsible for preparing the global organisation for launch into new therapeutic areas.

Dr. Wong's engagement leadership experience in consulting ranges from commercial strategy development, franchise planning, partnership opportunity identification, forecasting support, and pricing and market access strategy.

Dr. Wong holds a Doctor of Philosophy in Biology from University of California at San Diego, as well as a Bachelors in Molecular Biology from University of Texas at Austin.